Skip to main content
OpenTrials
Completed

NCT Number: NCT04400487

Actigraphy Improvement With Voxelotor (ActIVe) Study

This is a study to evaluate the effect of voxelotor on daily physical activity and sleep quality, as measured by a wrist-worn device in participants with sickle cell disease (SCD) and chronic moderate anemia.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Sickle Cell Disease Anemia Anemia, Hemolytic Anemia, Hemolytic, Congenital Anemia, Sickle Cell Congenital, Hereditary, and Neonatal Diseases and Abnormalities Genetic Diseases, Inborn Hematologic Diseases Hemic and Lymphatic Diseases Hemoglobinopathies Sickle Cell Anemia

Age range

12 year–55 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

UConn Health, Farmington, Connecticut, United States

Loading trial locations.

About this study

All participants will receive Voxelotor as treatment. There will be approximately 13 sites in the US.

Participant safety and tolerability will be monitored during the study using standard measures, including physical examinations, vital signs (including temperature, blood pressure, pulse rate, respiratory rate and peripheral oxygen saturation [SpO2]), clinical laboratory tests, and adverse event (AE) monitoring.

Screening Period (up to 4 weeks in duration): During this period, participants will sign the informed consent form (ICF), after which they will complete the screening assessments as detailed in the Schedule of Assessments (SOA).

Run-in Period (2 weeks in duration): During this period, participants will enter a 2-week run-in period (Day -14 to Day -1) during which baseline actigraphy measures of physical activity and sleep quality, overnight pulse oximetry assessments of oxygen saturation, and Patient-Reported Outcome (PRO) assessments will be collected before initiating treatment with voxelotor.

Treatment Period (24 weeks in duration): After completion of the 14-day Run-in Period, participants will enter the open label treatment period and receive voxelotor 1500 mg once daily for 24 weeks. Repeat actigraphy assessments of physical activity and sleep quality, and overnight pulse oximetry will be performed during the treatment period (Weeks 10 to 12 and Weeks 22 to 24). PRO and Clinical Global Impression (CGI) assessments will be completed at scheduled study visits. The open-label treatment period is considered the continuous 24 weeks of voxelotor treatment from date of first dose (Day 1).

Follow-up Period (4 weeks in duration): Immediately following the 24-week treatment period, participants will enter a 4-week Follow-up Period.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male or female participants with SCA (sickle hemoglobin with two sickle cell genes [HbSS] or sickle hemoglobin (S) and one beta thalassemia gene [HbS β0] thal genotype)
  • Between 12 to 55 years of age (inclusive)
  • Screening Hb level ≤8.0 g/dL
  • Treatment with hydroxyurea (HU) therapy on study is permitted if the participant has been on a stable dose for at least 90 days before enrollment with no dose modifications planned or anticipated by the Investigator
  • Treatment with glutamine is permitted
  • Treatment with erythropoiesis-stimulating agents (ESAs) is permitted if the participant has been on a stable dose for at least 12 weeks before enrollment with no dose modifications planned or anticipated by the Investigator
  • Female participants of child-bearing potential must use highly effective methods of contraception to 30 days after the last dose of study drug. Male participants must use barrier methods of contraception to 30 days after the last dose of study drug
  • Females of child-bearing potential are required to have a negative pregnancy test before the administration of study drug
  • Written informed consent and/or parental/guardian consent and participant assent per Institutional Review Board (IRB) policy and requirements, consistent with ICH guidelines

Exclusion criteria

  • Red blood cell (RBC transfusion within 3 months before initiation of study drug
  • Planned initiation of regularly scheduled RBC transfusion therapy (also termed chronic, prophylactic, or preventive transfusion) during the study
  • Hospitalization for vaso-occlusive crisis (VOC) or acute chest syndrome (ACS) within 30 days prior to informed consent/assent.
  • More than 10 VOCs requiring hospitalization, emergency department or clinic visit within the past 12 months
  • Planned elective surgery within the next 6 months
  • Physical inactivity attributable to clinically significant musculoskeletal, cardiovascular, or respiratory comorbidities
  • Anemia due to bone marrow failure (eg, myelodysplasia)
  • Absolute reticulocyte count (ARC) < 100 x10^9/L
  • Screening alanine aminotransferase (ALT) > 4× upper limit of normal (ULN)
  • Severe renal dysfunction (estimated glomerular filtration rate [GFR] < 30 mL/min/1.73 m2 by Schwartz formula) or is on chronic dialysis
  • Known active hepatitis A, B or C or known to be human immunodeficiency virus (HIV)-positive.
  • Females who are breast-feeding or pregnant
  • Major surgery within 8 weeks before enrollment. Participants must have completely recovered from any previous surgery before enrollment
  • History of hematopoietic stem cell transplant or gene therapy
  • Received an investigational drug within 30 days or 5-half-lives, whichever is longer, prior to consent, or is currently participating in another trial of an investigational or marketed drug (or medical device)
  • Use of concomitant medications (eg, crizanlizumab) that confound the ability to interpret data from the study
  • Medical, psychological, or behavioral condition that, in the opinion of the Investigator, would confound or interfere with evaluation of safety and/or efficacy of the study drug, prevent compliance with the study protocol; preclude informed consent; or, render the participant unable/unlikely to comply with the study procedures
  • Use of herbal medications (e.g., St. John's Wort), sensitive cytochrome P450 (CYP) 3A4 substrates with a narrow therapeutic index, strong CYP3A4 inhibitors, fluconazole, or moderate or strong CYP3A4 inducers
  • Symptomatic coronavirus disease of 2019 (COVID-19) infection

Treatment and study plan

Voxelotor

Drug

500 mg Tablet, Oral, With or Without Food

Other names: GBT440, Oxbryta

Primary outcomes

  1. Change From Baseline in Total Daily Physical Activity (Counts Per Minute) to Week 10-12

    Time frame: Baseline, Week 10-12

    Daily physical activity was measured by actigraphy in participants with sickle cell disease (SCD) and chronic moderate anemia. Actigraphy assessments were performed using wrist-worn tri-axial accelerometry device. Actigraphy is an accepted methodology for tracking activity levels, time spent in moderate and vigorous physical activity, step counts, and energy expenditure. Change from baseline to follow-up visit was calculated as the baseline measurement subtracted from the follow-up measurement for all assessments. In this outcome measure the average of at least 8 valid days during the specified two-week period was considered. A participant's daily wear must be 18 hours or more in a day to be considered a valid day.

  2. Change From Baseline in Total Daily Physical Activity (Counts Per Minute) to Week 22-24

    Time frame: Baseline, Week 22-24

    Daily physical activity was measured by actigraphy in participants with SCD and chronic moderate anemia. Actigraphy assessments were performed using wrist-worn tri-axial accelerometry device. Actigraphy is an accepted methodology for tracking activity levels, time spent in moderate and vigorous physical activity, step counts, and energy expenditure. Change from baseline to follow-up visit was calculated as the baseline measurement subtracted from the follow-up measurement for all assessments. In this outcome measure the average of at least 8 valid days during the specified two-week period was considered. A participant's daily wear must be 18 hours or more in a day to be considered a valid day.

  3. Change From Baseline in Light Physical Activity to Week 10-12

    Time frame: Baseline, Week 10-12

    Change in daily physical activity was measured by actigraphy in adolescent and adult participants with SCD and chronic moderate anemia. This outcome measure described the change from baseline in light physical activity. Change from baseline to follow-up visit was calculated as the baseline measurement subtracted from the follow-up measurement for all assessments. In this outcome measure the average of at least 8 valid days during the specified two-week period was considered. A participant's daily wear must be 18 hours or more in a day to be considered a valid day.

  4. Change From Baseline in Light Physical Activity to Week 22-24

    Time frame: Baseline, Week 22-24

    Change in daily physical activity was measured by actigraphy in adolescent and adult participants with SCD and chronic moderate anemia. This outcome measure described the change from baseline in light physical activity. Change from baseline to follow-up visit was calculated as the baseline measurement subtracted from the follow-up measurement for all assessments. In this outcome measure the average of at least 8 valid days during the specified two-week period was considered. A participant's daily wear must be 18 hours or more in a day to be considered a valid day.

  5. Change From Baseline in Moderate Physical Activity to Week 10-12

    Time frame: Baseline, Week 10-12

    Change in daily moderate physical activity (minutes per day) was measured by actigraphy in participants with SCD and chronic moderate anemia. Change from baseline to follow-up visit was calculated as the baseline measurement subtracted from the follow-up measurement for all assessments. In this outcome measure the average of at least 8 valid days during the specified two-week period was considered. A participant's daily wear must be 18 hours or more in a day to be considered a valid day.

  6. Change From Baseline in Moderate Physical Activity to Week 22-24

    Time frame: Baseline, Week 22-24

    Change in daily moderate physical activity (minutes per day) was measured by actigraphy in participants with SCD and chronic moderate anemia. Change from baseline to follow-up visit was calculated as the baseline measurement subtracted from the follow-up measurement for all assessments. In this outcome measure the average of at least 8 valid days during the specified two-week period was considered. A participant's daily wear must be 18 hours or more in a day to be considered a valid day.

  7. Change From Baseline in Vigorous Physical Activity to Week 10-12

    Time frame: Baseline, Week 10-12

    Change in daily vigorous physical activity (minutes per day) was measured by actigraphy in participants with SCD and chronic moderate anemia. Change from baseline to follow-up visit was calculated as the baseline measurement subtracted from the follow-up measurement for all assessments. In this outcome measure the average of at least 8 valid days during the specified two-week period was considered. A participant's daily wear must be 18 hours or more in a day to be considered a valid day.

  8. Change From Baseline in Vigorous Physical Activity to Week 22-24

    Time frame: Baseline, Week 22-24

    Change in daily vigorous physical activity (minutes per day) was measured by actigraphy in participants with SCD and chronic moderate anemia. Change from baseline to follow-up visit was calculated as the baseline measurement subtracted from the follow-up measurement for all assessments. In this outcome measure the average of at least 8 valid days during the specified two-week period was considered. A participant's daily wear must be 18 hours or more in a day to be considered a valid day.

  9. Change From Baseline in Total Nocturnal Sleep Time to Week 10-12

    Time frame: Baseline, Week 10-12

    Total nocturnal sleep time was measured by overnight actigraphy monitoring. Change from baseline to follow-up visit was calculated as the baseline measurement subtracted from the follow-up measurement for all assessments. In this outcome measure the average of at least 8 valid days during the specified two-week period was considered. A participant's daily wear must be 18 hours or more in a day to be considered a valid day.

  10. Change From Baseline in Total Nocturnal Sleep Time to Week 22-24

    Time frame: Baseline, Week 22-24

    Total nocturnal sleep time was measured by overnight actigraphy monitoring. Change from baseline to follow-up visit was calculated as the baseline measurement subtracted from the follow-up measurement for all assessments. In this outcome measure the average of at least 8 valid days during the specified two-week period was considered. A participant's daily wear must be 18 hours or more in a day to be considered a valid day.

  11. Change From Baseline in Wake Time After Sleep Onset to Week 10-12

    Time frame: Baseline, Week 10-12

    Measured by actigraphy monitoring. Change from baseline to follow-up visit was calculated as the baseline measurement subtracted from the follow-up measurement for all assessments. In this outcome measure the average of at least 8 valid days during the specified two-week period was considered. A participant's daily wear must be 18 hours or more in a day to be considered a valid day.

  12. Change From Baseline in Wake Time After Sleep Onset to Week 22-24

    Time frame: Baseline, Week 22-24

    Measured by actigraphy monitoring. Change from baseline to follow-up visit was calculated as the baseline measurement subtracted from the follow-up measurement for all assessments. In this outcome measure the average of at least 8 valid days during the specified two-week period was considered. A participant's daily wear must be 18 hours or more in a day to be considered a valid day.

  13. Change From Baseline in Sleep Efficiency to Week 10-12

    Time frame: Baseline, Week 10-12

    Sleep efficiency was defined as ration of total sleep time to time in bed. Change from baseline to follow-up visit was calculated as the baseline measurement subtracted from the follow-up measurement for all assessments.

  14. Change From Baseline in Sleep Efficiency to Week 22-24

    Time frame: Baseline, Week 22-24

    Sleep efficiency was defined as ration of total sleep time to time in bed. Change from baseline to follow-up visit was calculated as the baseline measurement subtracted from the follow-up measurement for all assessments.

  15. Percentage of Participants With a More Than (>)1 Grams Per Deciliter (g/dL) Increase in Hemoglobin (Hb) at Week 12

    Time frame: Week 12

  16. Percentage of Participants With a >1 g/dL Increase in Hemoglobin (Hb) at Week 24

    Time frame: Week 24

  17. Change From Baseline in Mean Overnight Oxygen Saturation (SpO2 Percentage [%]) to Week 10-12

    Time frame: Baseline, Week 10-12

  18. Change From Baseline in Mean Overnight SpO2 % to Week 22-24

    Time frame: Baseline, Week 22-24

  19. Change From Baseline in Median Number of Overnight SpO2 Dips > 3% Per Hour to Week 10-12

    Time frame: Baseline, Week 10-12

  20. Change From Baseline in Median Number of Overnight SpO2 Dips > 3% Per Hour to Week 22-24

    Time frame: Baseline, Week 22-24

Sponsors and collaborators

Lead sponsor

Pfizer

Industry

Registry information

Official study title

A Phase 4, Multicenter, Open-label Study to Evaluate the Treatment Effect of Voxelotor on Physical Activity in Adolescents and Adults With Sickle Cell Disease

Acronym: ActIVe

Important dates

Study start
2020
Primary completion
2022
Study completion
2022
First posted
May 22, 2020
Registry last updated
Nov 21, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.